• Home
  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Cardiology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma News
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Subscribe
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
Skip to content
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma News

BioPharma News

Biopharmaceutical industry analysis. Credible, reliable, equitable.

Subscribe
  • Home
  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Cardiology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma News
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Subscribe

Regulatory

Actions of government agencies regulating the pharmaceutical industry: approval, rejection, and prohibition of drugs, granting special statuses.

Posted inNeuroscience, New Drugs, Regulatory

Zynrelef: New Drug for Postoperative Pain Relief

by Tanya von Reuss May 17, 2021September 8, 2022

A proprietary formulation of bupivacaine with meloxicam, developed by Heron Therapeutics, relieves acute pain for 72 hours after surgery.

Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory

Zeposia: New Drug to Treat Relapsing Multiple Sclerosis

by Julia Mardi April 21, 2021September 8, 2022

Bristol-Myers Squibb has come up with ozanimod, a direct competitor to Novartis’ fingolimod and siponimod, for the treatment of multiple sclerosis.

Gastric cancer.
Posted inOncology, Regulatory

Opdivo and Keytruda: First-line Immunotherapy for Gastric Cancer and Esophageal Cancer

by Mark Gubar April 20, 2021September 8, 2022

Nivolumab or pembrolizumab should be added to standard chemotherapy to prolong the life of patients with gastric, esophageal, and gastroesophageal junction cancers.

Cancer.
Posted inNew Drugs, Oncology, Rare/Orphan Diseases, Regulatory

Danyelza: New Drug for Neuroblastoma That Can Cure It

by Julia Mardi and Mark Gubar April 16, 2021September 8, 2022

Naxitamab by Y-mAbs Therapeutics offers gorgeous treatment efficacy with unsafe adverse events.

Posted inNew Drugs, Rare/Orphan Diseases, Regulatory

Koselugo: First Drug to Treat Neurofibromatosis

by Tanya von Reuss April 14, 2021September 8, 2022

Selumetinib by AstraZeneca powerfully suppresses tumor growth in neurofibromatosis type 1.

Headache.
Posted inNeuroscience, New Drugs, Regulatory

Reyvow: Completely New Drug for Acute Treatment of Migraine

by Tanya von Reuss, Julia Mardi and Timur Burkhanayev April 13, 2021September 8, 2022

In the task of getting rid of headaches lasmiditan by Eli Lilly is as effective as the popular triptans, but safer.

Posted inNeuroscience, New Drugs, Rare/Orphan Diseases, Regulatory

Zolgensma: Gene Therapy That Cure Spinal Muscular Atrophy. The Most Comprehensive Review

by Tanya von Reuss, Mark Gubar, Alex Avisoni and Nik Resovski April 8, 2021September 8, 2022

Novartis revealed the most expensive drug in the world. And it is amazing.

Posts pagination

Newer posts 1 … 10 11 12 13 14 Older posts
BioPharma News Logo
Biopharmaceutical industry analysis.
© 2025 BioPharma News Powered by Newspack Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma News

Awareness and enlightenment are strengths.

BioPharma News is an amazing and trustworthy non-profit data analysis service that provides honest and objective reporting on the Pharma & Biotech industry. We would like to invite you to sign up for our weekly Newsletter to stay informed and uptodate.

Please check your inbox or spam folder for an email from [email protected] to confirm your subscription.

×